Saroja Pharma Industries India Ltd
₹ 58.0
9.34%
19 Nov
- close price
About
Incorporated in 2023, Saroja Pharma Ltd is mainly in the business of trading Thionyl Chloride chemical and pharmaceutical intermeddles, etc.[1]
Key Points
- Market Cap ₹ 23.3 Cr.
- Current Price ₹ 58.0
- High / Low ₹ 70.8 / 33.1
- Stock P/E 32.4
- Book Value ₹ 37.3
- Dividend Yield 0.00 %
- ROCE 14.9 %
- ROE 8.92 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Debtor days have increased from 106 to 146 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|
36.66 | 55.63 | 50.19 | 40.67 | 38.08 | |
35.36 | 53.53 | 47.47 | 38.11 | 35.75 | |
Operating Profit | 1.30 | 2.10 | 2.72 | 2.56 | 2.33 |
OPM % | 3.55% | 3.77% | 5.42% | 6.29% | 6.12% |
0.09 | 0.32 | 0.16 | 0.19 | 0.07 | |
Interest | 0.33 | 0.80 | 1.32 | 1.45 | 1.31 |
Depreciation | 0.02 | 0.05 | 0.07 | 0.09 | 0.11 |
Profit before tax | 1.04 | 1.57 | 1.49 | 1.21 | 0.98 |
Tax % | 28.85% | 28.03% | 28.86% | 27.27% | |
0.73 | 1.14 | 1.06 | 0.88 | 0.72 | |
EPS in Rs | 730.00 | 50.49 | 3.61 | 2.19 | 1.80 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 4% |
TTM: | -15% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 6% |
TTM: | -31% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 0% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 18% |
Last Year: | 9% |
Balance Sheet
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|
Equity Capital | 0.01 | 0.23 | 2.94 | 4.02 | 4.02 |
Reserves | 0.93 | 3.80 | 2.15 | 10.62 | 10.96 |
3.02 | 6.14 | 10.18 | 5.73 | 8.75 | |
4.26 | 5.34 | 6.07 | 6.20 | 5.17 | |
Total Liabilities | 8.22 | 15.51 | 21.34 | 26.57 | 28.90 |
0.09 | 0.34 | 2.22 | 2.51 | 2.47 | |
CWIP | 0.00 | 0.00 | 1.79 | 6.13 | 6.81 |
Investments | 0.00 | 0.04 | 0.14 | 0.20 | 0.25 |
8.13 | 15.13 | 17.19 | 17.73 | 19.37 | |
Total Assets | 8.22 | 15.51 | 21.34 | 26.57 | 28.90 |
Cash Flows
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
-1.05 | -3.67 | 2.19 | 1.02 | |
-0.05 | -0.34 | -4.82 | -4.76 | |
1.03 | 4.27 | 2.73 | 3.70 | |
Net Cash Flow | -0.07 | 0.26 | 0.10 | -0.04 |
Ratios
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Debtor Days | 71.88 | 91.73 | 80.80 | 145.75 |
Inventory Days | 7.23 | 3.41 | 31.18 | 4.10 |
Days Payable | 45.43 | 38.52 | 47.22 | 57.45 |
Cash Conversion Cycle | 33.68 | 56.62 | 64.76 | 92.39 |
Working Capital Days | 38.13 | 62.20 | 70.83 | 99.62 |
ROCE % | 33.55% | 22.09% | 14.93% |
Documents
Announcements
-
Statement of deviation(s) or variation(s) under Reg. 32
13 November 2024 - Saroja Pharma Industries India Limited has informed about statement of deviation(s) or variation(s) under Reg. 32
-
Financial Result Updates
13 November 2024 - Saroja Pharma Industries India Limited has submitted to the Exchange, the financial results for the period ended September 30, 2024.
-
Board Meeting Intimation
8 November 2024 - SAROJA PHARMA INDUSTRIES INDIA LIMITED has informed about Board Meeting to be held on 13-Nov-2024 to inter-alia consider and approve the Unaudited Financial results of …
-
Board Meeting Intimation
8 November 2024 - SAROJA PHARMA INDUSTRIES INDIA LIMITED has informed about Board Meeting to be held on 13-Nov-2024 to inter-alia consider and approve the Unaudited Financial results of …
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
20 October 2024 - Saroja Pharma Industries India Limited has informed about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Business Overview:[1]
SPIIL is in the business of trading in Pharma API, Pharma Intermediates, Chemicals, Solvents, and other pharmaceutical products, used
for human and veterinary medicine